- June Raine appointed interim chief
- Takes over from Ian Hudson, who is stepping down next month
The Medicines and Healthcare products Regulatory Agency has appointed an interim chief executive.
June Raine, the MHRA’s director of the vigilance and risk management of medicines division, will take over from Ian Hudson. Dr Hudson will be stepping down next month, after six years in the role.
Dr Raine qualified in medicine from Oxford University before undertaking research in pharmacology. She joined the then medicines division of the Department of Health in 1985, moving to the Medicines and Healthcare products Regulatory Agency when it was formed in 2003.
Dr Raine has worked in several medicines licensing and post-licensing areas, including medical devices, and became Director of the Agency’s Vigilance and Risk Management of Medicines division in 2006. She was chair of the European Pharmacovigilance Risk Assessment Committee on behalf of the European Medicines Agency from 2012 to 2018.
In a message to stakeholders, MHRA chairman Sir Michael Rawlins said: “Dr Raine has spent her professional career in the agency and its predecessor bodies. She is recognised as one of the leading experts in the field of medicines safety, playing a central role in the agency’s work. I am delighted that she has agreed to act as interim chief executive of the agency for the coming months.”
He added that Dr Hudson, who announced his resignation last year, had made a “very substantial contribution” to public health in the UK, Europe and globally during his 18 years with the MHRA, six as chief executive.
Information about a permanent replacement will be announced “in due course”, he added.